Nonavalent HPV vaccine's cost-effectiveness for Norway remains to be determined

Prev Med. 2021 Sep:150:106662. doi: 10.1016/j.ypmed.2021.106662. Epub 2021 Jul 21.

Authors

Elizabeth Goodman¹, Vincent Daniels², Andreas Rauscher², Margaret Stanley³

Affiliations

¹ Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: elizabeth.goodman@merck.com.
² Merck & Co., Inc., Kenilworth, NJ, USA.
³ Pathology, University of Cambridge, Cambridge, United Kingdom.

PMID: 34303488
DOI: 10.1016/j.ypmed.2021.106662

No abstract available

Publication types

Letter
Comment

MeSH terms

Cost-Benefit Analysis
Humans
Norway
Papillomavirus Infections* / prevention & control
Papillomavirus Vaccines*

Substances

Papillomavirus Vaccines